X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (259) 259
Publication (36) 36
Patent (6) 6
Book / eBook (5) 5
Web Resource (4) 4
Book Chapter (3) 3
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (155) 155
female (98) 98
male (95) 95
middle aged (95) 95
adult (93) 93
oncology (85) 85
antineoplastic combined chemotherapy protocols - therapeutic use (60) 60
hematology (56) 56
aged (55) 55
index medicus (48) 48
prognosis (43) 43
treatment outcome (39) 39
chemotherapy (38) 38
rituximab (38) 38
adolescent (36) 36
disease-free survival (35) 35
combined modality therapy (34) 34
follow-up studies (30) 30
hodgkin disease - drug therapy (30) 30
aged, 80 and over (29) 29
cyclophosphamide - administration & dosage (28) 28
hodgkin disease - therapy (28) 28
neoplasm staging (28) 28
vincristine - administration & dosage (27) 27
non-hodgkins-lymphoma (26) 26
prednisone - administration & dosage (26) 26
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
doxorubicin - administration & dosage (24) 24
therapy (24) 24
survival analysis (23) 23
survival rate (23) 23
transplantation, autologous (23) 23
lymphomas (22) 22
article (20) 20
cancer (20) 20
antibodies, monoclonal, murine-derived (19) 19
remission induction (19) 19
retrospective studies (19) 19
antineoplastic agents - therapeutic use (18) 18
hodgkin's disease (18) 18
lymphoma, non-hodgkin - therapy (18) 18
recurrence (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
disease (17) 17
etoposide - administration & dosage (17) 17
lymphoma (17) 17
drug administration schedule (16) 16
hodgkin disease - mortality (16) 16
hodgkin disease - radiotherapy (16) 16
survival (16) 16
follicular lymphoma (15) 15
hodgkin disease - pathology (15) 15
lymphoma, large b-cell, diffuse - drug therapy (15) 15
lymphoma, non-hodgkin - drug therapy (15) 15
antibodies, monoclonal - therapeutic use (14) 14
hematopoietic stem cell transplantation (14) 14
prospective studies (14) 14
transplantation (14) 14
young adult (14) 14
doxorubicin - therapeutic use (13) 13
bleomycin - administration & dosage (12) 12
lymphoma, non-hodgkin - mortality (12) 12
radiotherapy (12) 12
time factors (12) 12
bone marrow transplantation (11) 11
bone-marrow transplantation (11) 11
care and treatment (11) 11
cyclophosphamide (11) 11
abridged index medicus (10) 10
actuarial analysis (10) 10
age factors (10) 10
antibodies, monoclonal - administration & dosage (10) 10
b-cell lymphoma (10) 10
clinical trials as topic (10) 10
combination chemotherapy (10) 10
disease progression (10) 10
expression (10) 10
high-dose therapy (10) 10
lymphoma, large b-cell, diffuse - pathology (10) 10
lymphoma, non-hodgkin - pathology (10) 10
risk (10) 10
vinblastine - administration & dosage (10) 10
vincristine - therapeutic use (10) 10
anti-cd20 monoclonal-antibody (9) 9
antibodies, monoclonal, murine-derived - administration & dosage (9) 9
child (9) 9
etoposide (9) 9
lymphoma, follicular - drug therapy (9) 9
non-hodgkin's lymphomas (9) 9
original reports (9) 9
positron-emission-tomography (9) 9
prednisone - therapeutic use (9) 9
risk factors (9) 9
salvage therapy (9) 9
trial (9) 9
abvd (8) 8
antineoplastic agents - administration & dosage (8) 8
clinical trials (8) 8
cyclophosphamide - therapeutic use (8) 8
dacarbazine - administration & dosage (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2007, ISBN 0387343490, xv, 304
This book provides the necessary information about not only the clinical aspects of caring for cancer survivors, but also the psychosocial impacts. It will... 
psychology | therapy | Neoplasms | Survivors | Clinical & internal medicine | Cancer | Psychological aspects | Treatment | Rehabilitation | Patients | Oncology | Cancer Research | Medicine & Public Health | Hematology
Book
Science, ISSN 0036-8075, 03/2017, Volume 355, Issue 6330, pp. 1103 - 1103
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2004, Volume 22, Issue 8, pp. 1454 - 1459
Purpose To analyze the outcome of no initial therapy in stage I and II follicular small-cleaved (FSC) and follicular mixed (FM) non-Hodgkin's lymphoma (NHL) on... 
TRANSFORMATION | SURVIVAL | POLICY | ONCOLOGY | DISEASE | LOW-GRADE | COMMITTEE | NATURAL-HISTORY | EXPRESSION | CHEMOTHERAPY | Follow-Up Studies | Lymphoma, Follicular - pathology | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Survival Rate | Treatment Outcome | Disease Progression | Lymphoma, Non-Hodgkin - pathology | Time Factors | Adult | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Retrospective Studies
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 2702 - 2702
Abstract There is no single accepted treatment approach for mantle cell lymphoma (MCL), varying from intensive therapy in young, fit patients (pts) to less... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2015, Volume 171, Issue 4, p. 530
The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies... 
Analysis | Hemoglobin | Lymphomas
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3060 - 3060
Abstract Introduction The role of body mass index (BMI) impacting clinical outcome among lymphoma patients is controversial. Two recent studies suggest that... 
Journal Article
Leukemia and Lymphoma, ISSN 1042-8194, 03/2007, Volume 48, Issue 3, pp. 521 - 525
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 2636 - 2636
Abstract Introduction: There is no clear consensus regarding the optimal therapeutic approach for AYAs with HL. Prior registry data showed that HL AYA patients... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 399 - 408
In patients with limited-stage Hodgkin's disease, ABVD chemotherapy alone resulted in a higher rate of long-term (12-year) survival than either radiation... 
CLINICAL-PRACTICE GUIDELINES | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | RANDOMIZED-TRIALS | DISEASE | DOXORUBICIN | VINBLASTINE | BLEOMYCIN | FIELD RADIOTHERAPY | CHEMOTHERAPY | COOPERATIVE-ONCOLOGY-GROUP | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Radiotherapy - adverse effects | Vinblastine - therapeutic use | Cause of Death | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Hodgkin Disease - complications | Heart Diseases - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Neoplasm Staging | Doxorubicin - adverse effects | Drugs | Usage | Care and treatment | Vinblastine | Patient outcomes | Product/Service Evaluations | Radiotherapy | Doxorubicin | Dacarbazine | Bleomycin | Dosage and administration | Drug therapy, Combination | Drug therapy | Hodgkin's disease | Medical research | Clinical trials | Radiation therapy | Lymphoma | Survival | Patients | Chemotherapy | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2007, Volume 25, Issue 5, pp. 579 - 586
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 4277 - 4277
Abstract Background The international prognostic score (IPS) (Hasenclever et al., NEJM 1988) uses 7 factors (age> 45, male sex, hemoglobin<10.5, stage IV,... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 153 - 153
Abstract Abstract 153 Introduction Modified R-hyperCVAD is a well-tolerated induction regimen with a high response rate in MCL. We hypothesized that the... 
Journal Article